IL-5

IL-5

IL-5 詳細

Molecule Name
Interleukin-5
分子の別称
IL-5,TRF,IL5,Interleukin-5
Drug Development Progress
治験薬の数6
市販薬剤の数3
研究&開発段階Approved
ターゲットの別称
T-cell replacing factor,IL5,Interleukin 5,Eosinophil Differentiation Factor,Colony-Stimulating Factor, Eosinophil,B-Cell Differentiation Factor I,Interleukin-5,IL-5,TRF,Interleukin 5 (Colony-Stimulating Factor, Eosinophil),B Cell Differentiation Factor I,EDF
バックグランド
Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.

IL-5 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian)610; SSGJ-610Phase 3 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Asthma; Autoimmune Diseases
詳細
SHR-1703SHR-1703Phase 3 ClinicalJiangsu Hengrui Medicine Co Ltd
Asthma; Eosinophilic Asthma; Eosinophilic Granulomatosis With Polyangiitis
詳細
RC-1416RC14/16; RC-1416Phase 2 ClinicalNanjing RegeneCore Biotech Co Ltd
Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive
詳細
long-acting anti-IL-5 mAb (GSK)Phase 1 ClinicalGlaxosmithkline Plc
Asthma
詳細
Mepolizumab biosimilar(Bio Thera Solutions)BAT2606; BAT-2606Phase 1 ClinicalBio-Thera Solutions Ltd
Asthma; Autoimmune Diseases; Nasal Polyps; Sinusitis
詳細
Mepolizumab biosimilar (CTTQ Pharma)TQC-3566; TQC3566Phase 1 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Lymphohistiocytosis, Hemophagocytic; Nasal Polyps; Sinusitis; Vasculitis
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
ReslizumabCEP-38072; SCH-5570; TRFK-5; SCH-55700; CDP-835; CTx-55700ApprovedTeva Pharmaceutical Industries LtdCinquil, Cinqair, CinqaeroUnited StatesAsthmaTeva Respiratory Llc2016-03-23
Asthma; Bronchitis; Eosinophilic Esophagitis; Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia
詳細
DepemokimabGSK-3511294; AQ82742999; GSK3511294; GSK-294; GSK294ApprovedGlaxosmithkline Plc易适来, ExdensurUnited KingdomAsthma; Sinusitis; Nasal PolypsGlaxosmithkline Plc2025-12-15
Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Eosinophilic Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Vasculitis
詳細
MepolizumabSB-240563; 240563ApprovedGlaxosmithkline PlcBosatria, Nucala, 美泊利珠单抗, 新可来United StatesAsthmaGlaxosmithkline Llc2015-11-04
Angioedema; Asthma; Bronchitis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilia; Eosinophilic Esophagitis; Eosinophilic Granulomatosis With Polyangiitis; Fasciitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Virus Diseases
詳細